Saccharomyces boulardii does not prevent relapse of crohn's disease

Clinical Gastroenterology and Hepatology

Volumn 11, Issue 8, 2013, Pages 982-987

  Bourreille, Arnaud ^a   Cadiot, Guillaume ^b   Le Dreau, Gérard ^c   Laharie, David ^d   Beaugerie, Laurent ^e   Dupas, Jean Louis ^f   Marteau, Philippe ^g   Rampal, Patrick ^h   Moyse, Dominique ⁱ   Saleh, Ashraf ^j   Le Guern, Marie Emmanuelle ^j   Galmiche, Jean Paul ^a  

^a INSERM   (France)

^b SERVICE DE DERMATOLOGIE   (France)

^c Internal Medicine Department Allergy and Immunology Section Hotel Dieu de France Hospital   (France)

^d UNIVERSITÉ DE BORDEAUX   (France)

^e HÔPITAL SAINT ANTOINE   (France)

^f AMIENS UNIVERSITY HOSPITAL   (France)

^g UNIVERSITÉ PARIS DESCARTES   (France)

^h Princesse Grace Hospital   (Monaco)

ⁱ Consultant in Statistics ^*  (France)

^j Service de Pharmacologie   (France)

more..

Author keywords

IBD; Inflammatory bowel disease; Maintenance therapy; Microbiota

Indexed keywords

AMINOSALICYLIC ACID; C REACTIVE PROTEIN; FUNGAL EXTRACT; MESALAZINE; SACCHAROMYCES BOULARDII EXTRACT; STEROID; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; DOUBLE BLIND PROCEDURE; DRUG SAFETY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; POST HOC ANALYSIS; PROSPECTIVE STUDY; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RELAPSE; REMISSION; SACCHAROMYCES BOULARDII; STEROID THERAPY; TIME; TREATMENT DURATION;

ADVERSE EVENT; AE; C-REACTIVE PROTEIN; CD; CDAI; CI; CONFIDENCE INTERVAL; CROHN'S DISEASE; CROHN'S DISEASE ACTIVITY INDEX; CRP; ERYTHROCYTE SEDIMENTATION RATE; ESR; IBD; INFLAMMATORY BOWEL DISEASE; MAINTENANCE THERAPY; MICROBIOTA; MITT; MODIFIED INTENT-TO-TREAT; ODDS RATIO; OR; PER-PROTOCOL; PP;

ADOLESCENT; ADULT; AMINOSALICYLIC ACIDS; ANTI-INFLAMMATORY AGENTS; BIOLOGICAL THERAPY; CROHN DISEASE; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; PLACEBOS; PROBIOTICS; PROSPECTIVE STUDIES; RECURRENCE; SACCHAROMYCES; STEROIDS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84880587709     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2013.02.021     Document Type: Article

References (17)

1. Kirchhelle A., Frühwein N., Tobüren D. Treatment of persistent diarrhea with S. boulardii in returning travelers: results of prospective study. Fortschr Med 1996, 114:136-140.
2. Saint-Marc T., Blehaut H., Musial C., et al. Diarrhées en relation avec le SIDA: essai endouble aveugle de Saccharomyces boulardii. Sem Hop Paris 1995, 71:735-741.
3. McFarland L.V., Surawicz C.M., Greenberg R.N., et al. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 1994, 271:1913-1918.
4. Lee S.K., Kim Y.W., Chi S.G., et al. The effect of Saccharomyces boulardii on human colon cells and inflammation in rats with trinitrobenzene sulfonic acid-induced colitis. Dig Dis Sci 2009, 54:255-263.
5. Dalmasso G., Cottrez F., Imbert V., et al. Saccharomyces boulardii inhibits inflammatory bowel disease by trapping T cells in mesenteric lymph nodes. Gastroenterology 2006, 131:1812-1825.
6. Garcia Vilela E., De Lourdes De Abreu Ferrari M., Oswaldo Da Gama Torres H., et al. Influence of Saccharomyces boulardii on the intestinal permeability of patients with Crohn's disease in remission. Scand J Gastroenterol 2008, 43:842-848.
7. Plein K., Hotz J. Therapeutic effects of Saccharomyces boulardii on mild residual symptoms in a stable phase of Crohn's disease with special respect to chronic diarrhea: a pilot study. Z Gastroenterol 1993, 31:129-134.
8. Guslandi M., Mezzi G., Sorghi M., et al. Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig Dis Sci 2000, 45:1462-1464.
9. Ford A.C., Kane S.V., Khan K.J., et al. Efficacy of 5-aminosalicylates in Crohn's disease: systematic review and meta-analysis. Am J Gastroenterol 2011, 106:617-629.
10. Lim W., Hanauer S. Aminosalicylates for induction of remission or response in Crohn's disease. Cochrane Databse Syst Rev 2010, 12. CD008870.
11. Cosnes J., Carbonnel F., Carrat F., et al. Effects of current and former cigarette smoking on the clinical course of Crohn's disease. Aliment Pharmacol Ther 1999, 13:1403-1411.
12. Bibiloni R., Fedorak R.N., Tannock G.W., et al. VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol 2005, 100:1539-1546.
13. Mimura T., Rizzello F., Helwig U., et al. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut 2004, 53:108-114.
14. Gionchetti P., Rizzello F., Helwig U., et al. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology 2003, 124:1202-1209.
15. Rolfe V.E., Fortun P.J., Hawkey C.J., et al. Probiotics for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2006, 4. CD004826.
16. Shen J., Ran H.Z., Yin M.H., et al. Meta-analysis: the effect and adverse events of lactobacilli versus placebo in maintenance therapy for Crohn's disease. Intern Med J 2009, 39:103-109.
17. Doherty G.A., Bennett G.C., Cheifetz A.S., et al. Meta-analysis: targeting the intestinal microbiota in prophylaxis for post-operative Crohn's disease. Aliment Pharmacol Ther 2010, 31:802-809.